Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Youming Lei

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
Peerj|May 12, 2021
Identification of a novel autophagy signature for predicting survival in patients with lung adenocarcinomaJin Duan, Youming Lei, Guoli Lv, et al.
Anti-Cancer Drugs|February 2, 2023
First-line crizotinib therapy is effective for a novel SEC31A-anaplastic lymphoma kinase fusion in a patient with stage IV lung adenocarcinoma: a case report and literature reviewsRongrong Wu, Shinan Liu, Guoli Lv, et al.
Cancer Medicine|March 3, 2021
Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancerYunfei Shi, Youming Lei, Li Liu, et al.
BMC Cancer|December 5, 2025
Characterization of clinical risk factors for enhanced molecular residual disease monitoring in resected early-stage non-small cell lung cancerYunfei Shi, Youming Lei, Yinqiang Liu, et al.
Frontiers in Immunology|March 10, 2022
Various Subtypes of EGFR Mutations in Patients With NSCLC Define Genetic, Immunologic Diversity and Possess Different Prognostic BiomarkersYouming Lei, Kun Wang, Yinqiang Liu, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
Peerj|May 12, 2021
Identification of a novel autophagy signature for predicting survival in patients with lung adenocarcinomaJin Duan, Youming Lei, Guoli Lv, et al.
Anti-Cancer Drugs|February 2, 2023
First-line crizotinib therapy is effective for a novel SEC31A-anaplastic lymphoma kinase fusion in a patient with stage IV lung adenocarcinoma: a case report and literature reviewsRongrong Wu, Shinan Liu, Guoli Lv, et al.
Cancer Medicine|March 3, 2021
Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancerYunfei Shi, Youming Lei, Li Liu, et al.
BMC Cancer|December 5, 2025
Characterization of clinical risk factors for enhanced molecular residual disease monitoring in resected early-stage non-small cell lung cancerYunfei Shi, Youming Lei, Yinqiang Liu, et al.
Frontiers in Immunology|March 10, 2022
Various Subtypes of EGFR Mutations in Patients With NSCLC Define Genetic, Immunologic Diversity and Possess Different Prognostic BiomarkersYouming Lei, Kun Wang, Yinqiang Liu, et al.
Pageof 3